NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.394) was uploaded to the NHS England Website on Tuesday 21, April 2026.
The following changes have been introduced:
Encorafenib in combination with binimetinib (ENC3)
For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Zanidatamab (ZANI1)
For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Amivantamab in combination with lazertinib (AMI1)
For the first line treatment of locally advanced or metastatic non-small cell lung cancer in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations where the following criteria have been met
Moved into routine commissioning - section B of list
Blinatumomab (BLI3)
The treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:
Treatment criterion (#11) updated
Blinatumomab (BLI4)
The treatment of patients in first complete haematological remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria have been met:
Treatment criterion (#12) updated
Blinatumomab (BLI5)
The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met:
Treatment criteria (#4 and 10) updated
Blinatumomab (BLI6)
The treatment of POST PUBESCENT CHILDREN in first morphological complete remission and without minimal residual disease after 1st line intensive induction and any indicated intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia where the following criteria have been met
Treatment criterion (#4) updated
Dabrafenib in combination with trametinib (DABTRA3)
For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met
Treatment criteria (#1, 5 and 10 updated)
Pembrolizumab (PEMB5)
The treatment of relapsed or refractory classical Hodgkin lymphoma in ADULTS who are stem cell transplant-ineligible and have failed brentuximab vedotin where the following criteria have been met
Treatment criteria (#8, 9 and 12) updated
Pembrolizumab monotherapy (PEMB25)
For the treatment of patients with ENDOMETRIAL carcinoma exhibiting microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) and who have progressive disease during or following prior platinum-containing therapy given in any setting for advanced or recurrent or metastatic disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy where the following criteria have been met
Treatment criteria (#1, 8, 10 and 12) updated
Venetoclax in combination with azacitidine (VEN8)
For untreated adult acute myeloid leukaemia in patients unsuitable for intensive chemotherapy where the following criteria have been met
Treatment criteria (#5 and 11) updated
Pembrolizumab (PEMB34)
Pembrolizumab for resectable, locally advanced, head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more where the following criteria have been met
Date moving into routine commissioning updated